J.P. Morgan Week Digital, 11-13 January, 2021.

Every January, the J.P. Morgan Healthcare Conference in San Francisco has been a news-breaking, people-watching, deal making bazaar that sets the tone for the year to come. Join us on January 11–13 for this year’s virtual event exploring biopharma's ongoing work to combat COVID-19—and to fight the world's other diseases at the same time.

(November 2020)

LSX World Congress Digital, 1-5 February, 2021.

LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly listed life sciences giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.

In an industry as dynamic as the life science and healthcare sector, LSX World Congress brings the people who are tackling the biggest challenges in the industry today, and helps answer the question; “where to next and how do we get there“?

In 2021, the event will be a virtual experience incorporating all the same features of the usual physical meeting, but spread across a full week.

(November 2020)

Bio Europe Spring Digital, 22-25 March, 2021.

BIO-Europe Spring is the largest springtime partnering conference bringing together a “who’s who” from biotech, pharma and finance in the most innovative biopharma clusters in Europe. The conference offers countless opportunities to engage with global life science partners – this year in a virtual and secure format.

 

(November 2020)

Nordic Life Science Days Digital, 20-23 April, 2021.

NLS Days is the largest Nordic partnering conference dedicated to the life science industry. NLS Days offers networking and knowledge for anyone interested in the Nordic life science, biotech, pharma, medical devices and e-health business. It’s a space for meaningful encounters, with one-on-one meetings being one of the main features. Additionally, the high quality of topics and presenters provide insight into the most recent trends in science and business.

(May 2020)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4^th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

It is quite impressive that we have been able to live up to this four years in a row and we express our gratitude to our customers because without their continuous support and trust this would not have been possible.

(October 2019)

The new Xplico Evaluator template is now released

Xplico proudly releases a new and enhanced version of Xplico Evaluator, our valuation tool, available for all our subscription customers.

Many things have been changed behind the scene, with only a few changes in the way the assumptions are entered. The new version can handle more advanced Deal Terms and it has more features as well as additional outputs.

(June 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

Read the full article

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

Read the full article

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

Read the interview

(June 2018)